Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: Subanalysis of BELIEVE

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 9, 2011, Pages 1012-1020

  Ortonne, J P ^a   Chimenti, S ^b   Reich, K ^c   Gniadecki, R ^d   Sprogel P ^e   Unnebrink, K ^f   Kupper, H ^f   Goldblum, O ^g   Thaci D ^h  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c DERMATOLOGIKUM HAMBURG   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e LEO PHARMA A S   (Denmark)

^f ABBOTT GMBH AND CO KG   (Germany)

^g ABBOTT LABORATORIES   (United States)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

adalimumab; etanercept; infliximab; psoriasis; treatment outcome; tumour necrosis factor antagonist

Indexed keywords

ADALIMUMAB; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LIVER DISEASE; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OPPORTUNISTIC INFECTION; POST HOC ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; TOPICAL TREATMENT; TUBERCULOSIS;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BETAMETHASONE; CALCITRIOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051692385     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03944.x     Document Type: Article

References (17)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850. (Pubitemid 351509656)
2. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
3. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
4. Haitz KA, Kalb RE,. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol 2007; 57: 120-125. (Pubitemid 46899280)
5. Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V,. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008; 216: 312-316. (Pubitemid 351630095)
6. Van L, Modi SV, Yang DJ, Hsu S,. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol 2008; 144: 804-806. (Pubitemid 351846889)
7. Martyn-Simmons C, Green L, Ash G, Groves R, Smith C, Barker J,. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-1397.
8. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275. (Pubitemid 47048857)
9. Yamauchi PS, Mau N,. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol 2009; 61: 158-160.
10. Bissonnette RBC, Poulin Y, Guenther L, Lynde C, Maari C,. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010; 63: 228-234.
11. Cassano N, Galluccio A, De Simone C, et al. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents 2008; 22: 233-237.
12. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-411.
13. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566. (Pubitemid 351239154)
14. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115. (Pubitemid 350298146)
15. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308-316.
16. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838. (Pubitemid 351650483)
17. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-1199. (Pubitemid 47053782)